Join to View Full Profile
200 1st Street SWRochester, MN 55905
Dr. Hampel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2018 - 2021- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2015 - 2018
University of Missouri-Columbia School of MedicineClass of 2015
Certifications & Licensure
MN State Medical License 2016 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC Recommendations.Adam S Kittai, Monia Marchetti, Othman Al-Sawaf, Ohad Benjamini, Alexey V Danilov
Blood. 2025-04-16 - A pilot study to determine the feasibility and safety of pharmacist and nurse driven management of venetoclax ramp-up in patients with chronic lymphocytic leukemia.Rachel J Bailen, Monica I Aasum, Linda M Tamminga, Amber B Koehler, Amy L Behnken
Journal of Oncology Pharmacy Practice. 2025-04-01 - 1 citationsOutcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLL.Adam S Kittai, Ying Huang, Sarah Miller, John N Allan, Seema A Bhat
Blood Cancer Journal. 2025-02-20
Journal Articles
- Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib in Routine Clinical Practice at an Academic Medical CentreSameer A Parikh, Tait D Shanafelt, Paul J Hampel, Jose F Leis, Neil E Kay, Wei Ding, Timothy G Call, Deborah Bowen, Eli Muchtar, British Journal of Haematology
Lectures
- BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
